based on:

• Risk classification of the product (sterile, biologics, cytotoxic, etc.)
• Volume and frequency of supply to Brazil
• Past non-compliances or delays in CAPA closure
• Global safety signals and pharmacovigilance triggers

Risk assessments follow a decision matrix that ranks facilities as high, medium, or low risk

GMP Audit Workflow: ANVISA’s Process

1. Notice of inspection issued (except in unannounced audits)
2. Audit team appointed based on product class and regulatory complexity
3. On-site review of:
   • Quality system and deviation records
   • Equipment qualification and process validation
   • SOPs, batch records, and document control systems
   • Data integrity (audit trails, backups, and user access management)
   • Analytical methods and validation reports
4. Closing meeting summarizing findings and expectations
5. Inspection report and deficiency notice issued with deadline for CAPA

Deficiency Classification by ANVISA

• Observations classified into:
  • Critical: Risks that may directly affect patient safety or lead to regulatory breach
  • Major: Significant deviations from GMP that impact product quality
  • Minor: Technical non-conformities without immediate safety risk
• Three or more Major deficiencies may elevate the facility to Non-Compliant status
• Any Critical deficiency mandates immediate containment or suspension actions

Common GMP Issues Identified by ANVISA

• Incomplete validation of cleaning and equipment qualification
• Uncontrolled electronic records and absence of audit trails
• Inadequate handling of deviations and late CAPA closures
• Poor training documentation and job-role mapping
• Lack of trending reports in stability programs

Post-Inspection: CAPA Submission and Follow-Up

1. Companies must submit a CAPA plan within 30 calendar days
2. CAPA must include:
   • Root cause analysis (RCA)
   • Corrective and preventive actions
   • Responsible personnel and implementation timelines
   • Effectiveness verification plan
3. ANVISA may request additional evidence or schedule a re-inspection
4. Final GMP Certification or Rejection issued based on CAPA review

GMP Certification and Licensing

• Facilities passing inspection are granted a GMP Certificate valid for 2 years (domestic) or 2–3 years (foreign)
• Certificate is mandatory for product registration, import clearance, and market access
• Foreign sites must be linked to a Brazilian sponsor responsible for regulatory liaison

Digitalization and Inspection Trends

• ANVISA increasingly reviews:
  • Electronic Batch Manufacturing Records (e-BMR)
  • Cloud-based LIMS and QMS solutions
  • Data integrity compliance per ALCOA+ standards
• Remote and hybrid inspections introduced for selected cases (e.g., COVID-19, re-inspections)
• Enhanced focus on cybersecurity, access control, and e-signature integrity

International Recognition and Reliance

• ANVISA is a PIC/S member and increasingly aligned with:
  • EMA, WHO PQP, and US FDA in mutual recognition initiatives
  • Latin American harmonization efforts via Mercosur and regional health alliances
• GMP Certificates from ANVISA are often recognized in other South American countries
• Used as part of donor agency compliance submissions for essential medicine tenders

Best Practices for Manufacturers Targeting Brazil

1. Align QMS, documentation, and SOPs with RDC No. 301 and PIC/S guidelines
2. Prepare an accurate Site Master File (translated if applicable)
3. Maintain full traceability of all deviations, CAPAs, and change control activities
4. Ensure validation protocols are current and inclusive of worst-case scenarios
5. Use audit readiness tools to simulate inspections based on past ANVISA findings

Conclusion

Brazil’s ANVISA enforces one of the most structured GMP inspection models in Latin America, serving both domestic oversight and international quality convergence. By understanding ANVISA’s regulatory expectations and preparing accordingly, pharmaceutical companies can enhance their compliance posture, secure GMP certification, and confidently access one of the region’s largest pharmaceutical markets.